☰

Milton C. Weinstein - Publications

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
Epidemiology, Public Health, Operations Research, General Economics
Tree Info Similar researchers PubMed Report error

278 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Pei PP, Fitzmaurice KP, Le MH, Panella C, Jones ML, Pandya A, Horsburgh CR, Freedberg KA, Weinstein MC, Paltiel AD, Reddy KP. The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis. Mdm Policy & Practice. 8: 23814683231198873. PMID 37743931 DOI: 10.1177/23814683231198873  0.515
2021 Neilan AM, Bangs AC, Hudgens M, Patel K, Agwu AL, Bassett IV, Gaur AH, Hyle EP, Crespi CM, Horvath KJ, Dugdale CM, Powers KA, Rendina HJ, Weinstein MC, Walensky RP, et al. Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. Aids and Behavior. PMID 33547993 DOI: 10.1007/s10461-021-03169-0  0.327
2020 Neilan AM, Losina E, Bangs AC, Flanagan C, Panella C, Eskibozkurt GE, Mohareb A, Hyle EP, Scott JA, Weinstein MC, Siedner MJ, Reddy KP, Harling G, Freedberg KA, Shebl FM, et al. Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32945845 DOI: 10.1093/Cid/Ciaa1418  0.371
2020 Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of frequent HIV screening among high-risk young men who have sex with men in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32730625 DOI: 10.1093/Cid/Ciaa1061  0.658
2020 Soeteman DI, Resch SC, Jalal H, Dugdale CM, Penazzato M, Weinstein MC, Phillips A, Hou T, Abrams EJ, Dunning L, Newell ML, Pei PP, Freedberg KA, Walensky RP, Ciaranello AL. Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. Mdm Policy & Practice. 5: 2381468320932894. PMID 32587893 DOI: 10.1177/2381468320932894  0.614
2020 Kazemian P, Costantini S, Neilan AM, Resch SC, Walensky RP, Weinstein MC, Freedberg KA. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. Journal of Biomedical Informatics. 103475. PMID 32526280 DOI: 10.1016/J.Jbi.2020.103475  0.651
2020 Hathway JM, Miller-Wilson LA, Jensen IS, Ozbay B, Regan C, Jena AB, Weinstein MC, Parks PD. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. Journal of Medical Economics. 1. PMID 32063100 DOI: 10.1080/13696998.2020.1730123  0.323
2019 Dugdale CM, Phillips TK, Myer L, Hyle EP, Brittain K, Freedberg KA, Cunnama L, Walensky RP, Zerbe A, Weinstein MC, Abrams EJ, Ciaranello AL. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. Plos One. 14: e0225104. PMID 31730630 DOI: 10.1371/Journal.Pone.0225104  0.342
2019 Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, Weinstein MC. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. American Heart Journal. 214: 77-87. PMID 31174054 DOI: 10.1016/J.Ahj.2019.04.020  0.555
2019 Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31055599 DOI: 10.1093/Cid/Ciz372  0.379
2019 Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders. Pharmacoeconomics. PMID 30895565 DOI: 10.1007/S40273-019-00783-8  0.7
2018 Pandya A, Asch DA, Volpp KG, Sy S, Troxel AB, Zhu J, Weinstein MC, Rosenthal MB, Gaziano TA. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. Jama Network Open. 1: e182008. PMID 30646152 DOI: 10.1001/jamanetworkopen.2018.2008  0.503
2018 Garrison LP, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 161-165. PMID 29477394 DOI: 10.1016/J.Jval.2017.12.009  0.373
2018 Shrime MG, Weinstein MC, Hammitt JK, Cohen JL, Salomon JA. Trading Bankruptcy for Health: A Discrete-Choice Experiment. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 95-104. PMID 29304947 DOI: 10.1016/J.Jval.2017.07.006  0.333
2017 Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal of Infectious Diseases. PMID 29029344 DOI: 10.1093/Infdis/Jix349  0.361
2017 Walensky RP, Borre ED, Bekker LG, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Anglaret X, Freedberg KA, Paltiel AD. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Annals of Internal Medicine. PMID 28847013 DOI: 10.7326/M17-1358  0.332
2017 Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases. 4: ofx081. PMID 28680903 DOI: 10.1093/Ofid/Ofx081  0.414
2017 Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA. Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28605504 DOI: 10.1093/Cid/Cix547  0.338
2017 Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease Policy Micro-Simulation Model using Both Survival and Receiver Operating Characteristic Curves. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X17706081. PMID 28490271 DOI: 10.1177/0272989X17706081  0.563
2017 Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infectious Diseases. 4: ofw266. PMID 28480259 DOI: 10.1093/Ofid/Ofw266  0.581
2017 Fust K, Parthan A, Maschio M, Gu Q, Li X, Lyman GH, Tzivelekis S, Villa G, Weinstein MC. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 28064553 DOI: 10.1080/14737167.2017.1276829  0.345
2016 Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. Pharmacoeconomics. PMID 27928760 DOI: 10.1007/S40273-016-0474-0  0.321
2016 Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, Walensky RP, Leroy V, Weinstein MC, Parker RA, Freedberg KA, Ciaranello A. Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa: Test timing and frequency. The Journal of Infectious Diseases. PMID 27540110 DOI: 10.1093/Infdis/Jiw379  0.343
2016 Malone DC, Berg NS, Claxton K, Garrison LP, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298420 DOI: 10.1200/Jco.2015.64.4328  0.33
2016 Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Annals of Internal Medicine. PMID 27240120 DOI: 10.7326/M16-0799  0.642
2015 Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The cost-effectiveness and budget impact of two-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26658053 DOI: 10.1093/Cid/Civ981  0.448
2015 Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. Hiv Clinical Trials. 1-12. PMID 26651525 DOI: 10.1080/15284336.2015.1123942  0.573
2015 Pandya A, Weinstein MC, Gaziano TA. Cost-effectiveness of Statin Therapy for ASCVD--Reply. Jama. 314: 2191-2. PMID 26599190 DOI: 10.1001/Jama.2015.12928  0.591
2015 Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, Gazelle GS, Weinstein MC, Gaziano TA. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation. Cardiovascular Quality and Outcomes. 8: 621-30. PMID 26555126 DOI: 10.1161/Circoutcomes.115.002002  0.341
2015 Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. Hiv Clinical Trials. 1945577115Y000000000. PMID 26365741 DOI: 10.1179/1945577115Y.0000000009  0.523
2015 Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. Jama. 314: 142-50. PMID 26172894 DOI: 10.1001/Jama.2015.6822  0.553
2015 Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC. Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion. Health Affairs (Project Hope). 34: 1234-40. PMID 26135209 DOI: 10.1377/Hlthaff.2014.1274  0.351
2015 Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, Walensky RP, Essajee S, Losina E, Muhe L, Wools-Kaloustian K, Ayaya S, Weinstein MC, Palumbo P, Freedberg KA. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. Aids (London, England). 29: 1247-59. PMID 25870982 DOI: 10.1097/Qad.0000000000000672  0.375
2015 Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Annals of Internal Medicine. 162: 619-29. PMID 25820703 DOI: 10.7326/M14-1313  0.532
2015 Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The lifetime medical cost savings from preventing HIV in the United States. Medical Care. 53: 293-301. PMID 25710311 DOI: 10.1097/Mlr.0000000000000308  0.618
2015 Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 60: 1102-10. PMID 25583979 DOI: 10.1093/Cid/Ciu1159  0.611
2015 Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein M, Somers L, Hoefkens C, Lyman G. Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma Value in Health. 18: A204. DOI: 10.1016/J.Jval.2015.03.1181  0.315
2015 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M, Mueller U, Tang B, Pathak A, Weinstein M. Cost-Effectiveness Analysis of Arsenic Trioxide for The Treatment of In Patients With Acute Promyelocytic Leukemia Value in Health. 18: A202. DOI: 10.1016/J.Jval.2015.03.1170  0.36
2014 Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR, Walensky RP, Weinstein MC, Eron J, Freedberg KA. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? Plos One. 9: e113031. PMID 25397616 DOI: 10.1371/Journal.Pone.0113031  0.429
2014 Ross E, Tanser F, Pei P, Newell ML, Losina E, Thiebaut R, Weinstein M, Freedberg K, Anglaret X, Scott C, Dabis F, Walensky R. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. Hiv Clinical Trials. 15: 185-98. PMID 25350957 DOI: 10.1310/Hct1505-185  0.343
2014 Jönsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, Jönsson B, Weinstein MC, Drummond M. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: 707-13. PMID 25236994 DOI: 10.1016/J.Jval.2014.06.006  0.324
2014 Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. The New England Journal of Medicine. 371: 796-7. PMID 25162885 DOI: 10.1056/Nejmp1405158  0.333
2014 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. Plos One. 9: e97317. PMID 24842841 DOI: 10.1371/Journal.Pone.0097317  0.522
2014 Phelps CE, O'Sullivan AK, Ladapo JA, Weinstein MC, Leahy K, Douglas PS. Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease. American Heart Journal. 167: 697-706.e2. PMID 24766980 DOI: 10.1016/J.Ahj.2014.02.005  0.327
2014 Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. Aids (London, England). 28: 365-76. PMID 24670522 DOI: 10.1097/Qad.0000000000000093  0.577
2014 Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic Oncology. 133: 446-53. PMID 24657302 DOI: 10.1016/J.Ygyno.2014.03.014  0.347
2014 Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Economic burden of childhood autism spectrum disorders. Pediatrics. 133: e520-9. PMID 24515505 DOI: 10.1542/Peds.2013-0763  0.716
2014 Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, Gazelle GS, Weinstein MC. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer. 120: 1345-52. PMID 24481684 DOI: 10.1002/Cncr.28562  0.345
2014 Pandya A, Weinstein MC, Salomon JA, Cutler D, Gaziano TA. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circulation. Cardiovascular Quality and Outcomes. 7: 25-32. PMID 24425701 DOI: 10.1161/Circoutcomes.113.000397  0.564
2014 Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. Journal of Medical Economics. 17: 32-42. PMID 24028444 DOI: 10.3111/13696998.2013.844160  0.342
2014 Fust K, Kohli M, Ball G, Kawai K, Acosta C, Weinstein M. Do Utility Values Reflect Lost Income And The Full Opportunity Cost Of Work Loss? Value in Health. 17: A163-A164. DOI: 10.1016/J.Jval.2014.03.952  0.343
2013 Ciaranello AL, Morris BL, Walensky RP, Weinstein MC, Ayaya S, Doherty K, Leroy V, Hou T, Desmonde S, Lu Z, Noubary F, Patel K, Ramirez-Avila L, Losina E, Seage GR, et al. Validation and calibration of a computer simulation model of pediatric HIV infection. Plos One. 8: e83389. PMID 24349503 DOI: 10.1371/Journal.Pone.0083389  0.378
2013 Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. The New England Journal of Medicine. 369: 1715-25. PMID 24171517 DOI: 10.1056/Nejmsa1214720  0.43
2013 Pandya A, Gaziano TA, Weinstein MC, Cutler D. More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Affairs (Project Hope). 32: 1706-14. PMID 24101059 DOI: 10.1377/Hlthaff.2013.0449  0.531
2013 McGarry LJ, Krishnarajah G, Hill G, Skornicki M, Pruttivarasin N, Masseria C, Arondekar B, Pelton SI, Weinstein MC. Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. Plos One. 8: e67260. PMID 24019859 DOI: 10.1371/Journal.Pone.0067260  0.314
2013 Parthan A, Leahy KJ, O'Sullivan AK, Iakoubova OA, Bare LA, Devlin JJ, Weinstein MC. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome. Pharmacoeconomics. 31: 519-31. PMID 23585310 DOI: 10.1007/S40273-013-0054-5  0.31
2013 Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine. 158: 84-92. PMID 23318310 DOI: 10.7326/0003-4819-158-2-201301150-00002  0.628
2013 Clements K, Hulbert E, Panchmatia H, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein M. Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden Value in Health. 16: A506. DOI: 10.1016/J.Jval.2013.08.1168  0.327
2013 Fust K, Li X, Maschio M, Barron R, Weinstein M, Parthan A, Walli-Attaei M, Chandler D, Lyman G. Cost-Effectiveness Of Prophylaxis Treatment Strategies For Febrile Neutropenia In Recurrent Ovarian Cancer Patients Value in Health. 16: A140. DOI: 10.1016/J.Jval.2013.03.685  0.354
2013 Fust K, Weinstein M, Gomez-Rey G, Xie Y, Hsu T, Pawar V, Hsu L, Tan B, O'Sullivan A. Cost-Effectiveness Of Posaconazole Versus Fluconazole/ Itraconazole In The Prevention Of Invasive Fungal Infections Among High-Risk Neutropenic Patients In Singapore Value in Health. 16: A138-A139. DOI: 10.1016/J.Jval.2013.03.677  0.363
2012 Kimmel AD, Resch SC, Anglaret X, Daniels N, Goldie SJ, Danel C, Wong AY, Freedberg KA, Weinstein MC. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Effectiveness and Resource Allocation : C/E. 10: 12. PMID 22992315 DOI: 10.1186/1478-7547-10-12  0.789
2012 Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. Aids (London, England). 26: 1083-93. PMID 22343964 DOI: 10.1097/Qad.0B013E32835221Eb  0.316
2012 O'Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA, Perfect JR, Papadopoulos G. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 69: 149-56. PMID 22215361 DOI: 10.2146/Ajhp110149  0.557
2012 McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (Baltimore, Md.). 55: 1344-55. PMID 22135116 DOI: 10.1002/Hep.25510  0.335
2012 Lawrence D, Maschio M, Yunger S, Easaw J, Aucoin N, Weinstein M. Canadian Economic Analysis of Bevacizumab, Cetuximab, and Panitumumab in the First Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer (MCRC) Annals of Oncology. 23: ix202. DOI: 10.1016/S0923-7534(20)33207-5  0.417
2011 Parthan A, Pruttivarasin N, Taylor D, Davies D, Yang G, Pawar V, Weinstein MC. CyberKnife for prostate cancer: Is it cost-effective? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 87. PMID 27968370 DOI: 10.1200/Jco.2011.29.7_Suppl.87  0.314
2011 Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein MC, Weinstein JN. Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine. 36: 2061-8. PMID 22048651 DOI: 10.1097/Brs.0B013E318235457B  0.321
2011 McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, Johnson BE, Weeks JC, Gazelle GS. Cost-effectiveness of computed tomography screening for lung cancer in the United States. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1841-8. PMID 21892105 DOI: 10.1097/Jto.0B013E31822E59B3  0.321
2011 Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC. Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 14: 700-4. PMID 21839408 DOI: 10.1016/J.Jval.2011.01.002  0.491
2011 Pandya A, Weinstein MC, Gaziano TA. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. Plos One. 6: e20416. PMID 21655241 DOI: 10.1371/Journal.Pone.0020416  0.505
2011 Parthan A, Pruttivarasin N, Taylor D, Davies D, Yang G, Pawar V, Weinstein M. PMD21 IS CYBERKNIFE A COST-EFFECTIVE OPTION FOR TREATING PROSTATE CANCER? Value in Health. 14: A82-A83. DOI: 10.1016/J.Jval.2011.02.461  0.305
2010 Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. The New England Journal of Medicine. 363: 1495-7. PMID 20942664 DOI: 10.1056/Nejmp1007168  0.385
2010 Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 28: 995-1000. PMID 20936883 DOI: 10.2165/11538660-000000000-00000  0.507
2010 Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, Goldie SJ. Assessing the performance of a computer-based policy model of HIV and AIDS. Plos One. 5. PMID 20844741 DOI: 10.1371/Journal.Pone.0012647  0.368
2010 Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, Messou E, Cotich KL, Walensky RP, Freedberg KA. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. Journal of Acquired Immune Deficiency Syndromes (1999). 54: 258-68. PMID 20404739 DOI: 10.1097/Qai.0B013E3181D0Db97  0.72
2010 McGarry LJ, Merchant S, Nathwani D, Pawar V, DeLong K, Thompson D, Akhras K, Ingham M, Weinstein MC. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Journal of Medical Economics. 13: 142-7. PMID 20136579 DOI: 10.3111/13696991003604108  0.338
2010 Weinstein MC, Skinner JA. Comparative effectiveness and health care spending--implications for reform. The New England Journal of Medicine. 362: 460-5. PMID 20054039 DOI: 10.1056/Nejmsb0911104  0.368
2010 Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, Waters DD, Drummond M, Weinstein MC. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 28: 47-60. PMID 20014876 DOI: 10.2165/11531440-000000000-00000  0.523
2010 Taylor D, Pawar V, Gilmore K, Sanon M, Kruzikas D, Kohli M, Arondekar B, Demarteau N, Weinstein M. PIH22 EVALUATING THE COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING AND HUMAN PAPILLOMAVIRUS VACCINATION STRATEGIES USING A MATHEMATICAL MODEL Value in Health. 13: A378-A379. DOI: 10.1016/S1098-3015(11)72537-2  0.316
2010 Ekman M, Charbonneau C, Ramsberg J, Jonsson L, Sandin R, Jonsson B, Drummond M, Weinstein M. PCN162 EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: IN SEARCH OF A STANDARD Value in Health. 13: A282. DOI: 10.1016/S1098-3015(11)72053-8  0.37
2010 Campbell J, Taylor D, Skornicki M, Sood V, Arondekar B, Weinstein M. PIN21 COST-EFFECTIVENESS OF THE ACIP RECOMMENDED ADULT IMMUNIZATION SCHEDULE IN THE US Value in Health. 13: A190. DOI: 10.1016/S1098-3015(10)72928-4  0.33
2009 Ladapo JA, Jaffer FA, Hoffmann U, Thomson CC, Bamberg F, Dec W, Cutler DM, Weinstein MC, Gazelle GS. Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. Journal of the American College of Cardiology. 54: 2409-22. PMID 20082932 DOI: 10.1016/J.Jacc.2009.10.012  0.327
2009 Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. Plos Medicine. 6: e1000173. PMID 19859538 DOI: 10.1371/Journal.Pmed.1000173  0.419
2009 Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 49: 1570-8. PMID 19845472 DOI: 10.1086/644772  0.594
2009 Ruger JP, Emmons KM, Kearney MH, Weinstein MC. Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women. Bmc Pregnancy and Childbirth. 9: 46. PMID 19775455 DOI: 10.1186/1471-2393-9-46  0.365
2009 Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals of Internal Medicine. 151: 157-66. PMID 19620143 DOI: 10.7326/0003-4819-151-3-200908040-00138  0.303
2009 O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 666-73. PMID 19508661 DOI: 10.1111/J.1524-4733.2008.00486.X  0.581
2009 Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: S5-9. PMID 19250132 DOI: 10.1111/J.1524-4733.2009.00515.X  0.335
2009 O'Sullivan AK, Thompson D, Chu P, Lee DW, Stewart EA, Weinstein MC. Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. International Journal of Technology Assessment in Health Care. 25: 14-25. PMID 19126247 DOI: 10.1017/S0266462309090035  0.321
2009 Taylor DC, Pandya A, Thompson D, Chu P, Graff J, Shepherd J, Wenger N, Greten H, Carmena R, Drummond M, Weinstein MC. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 10: 255-65. PMID 18800232 DOI: 10.1007/S10198-008-0126-1  0.576
2009 Bentley TG, Weinstein MC, Willett WC, Kuntz KM. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutrition. 12: 455-67. PMID 18590584 DOI: 10.1017/S1368980008002565  0.316
2008 Ciaranello AL, Seage GR, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. Aids (London, England). 22: 2359-69. PMID 18981776 DOI: 10.1097/Qad.0B013E3283189Bd7  0.313
2008 Ladapo JA, Hoffmann U, Bamberg F, Nagurney JT, Cutler DM, Weinstein MC, Gazelle GS. Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. Ajr. American Journal of Roentgenology. 191: 455-63. PMID 18647917 DOI: 10.2214/Ajr.07.3611  0.305
2008 Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. The Journal of Infectious Diseases. 197: 1324-32. PMID 18422445 DOI: 10.1086/587184  0.342
2008 Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 213-20. PMID 18380633 DOI: 10.1111/J.1524-4733.2007.00226.X  0.326
2008 Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Medical Care. 46: 343-5. PMID 18362811 DOI: 10.1097/Mlr.0B013E31816A7144  0.409
2008 Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. The New England Journal of Medicine. 358: 661-3. PMID 18272889 DOI: 10.1056/Nejmp0708558  0.355
2008 Ruger JP, Weinstein MC, Hammond SK, Kearney MH, Emmons KM. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 191-8. PMID 17854434 DOI: 10.1111/J.1524-4733.2007.00240.X  0.317
2008 Thompson D, O'Sullivan A, Rubin J, Nyambose J, Kuznik A, Lee F, Cohen D, Crown W, Weinstein M. Pcv51 A Flexible Tool To Estimate Medical-Care Costs For Study Events In Cardiovascular Endpointtrials Value in Health. 11. DOI: 10.1016/S1098-3015(10)70639-2  0.327
2008 LJ M, Merchant S, Pawar V, Delong K, Thompson D, Akhras K, Ingham M, Weinstein M. IN4 COST-EFFECTIVENESS OF DORIPENEM INTHETREATMENT OF NOSOCOMIAL PNEUMONIA Value in Health. 11: A25. DOI: 10.1016/S1098-3015(10)70091-7  0.392
2008 Rosen V, Taylor D, Parekh H, Pandya A, Thompson D, Kuznik A, Waters D, Drummond M, Weinstein M. Cost-Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure in the US Journal of Cardiac Failure. 14: S81. DOI: 10.1016/J.Cardfail.2008.06.446  0.549
2007 Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: S248-54. PMID 18190295 DOI: 10.1086/522546  0.448
2007 Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 10: 367-76. PMID 17888101 DOI: 10.1111/J.1524-4733.2007.00190.X  0.352
2007 Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: 1062-70. PMID 17879926 DOI: 10.1086/521933  0.578
2007 Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. Hiv Medicine. 8: 439-50. PMID 17760736 DOI: 10.1111/J.1468-1293.2007.00491.X  0.363
2007 Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. Aids (London, England). 21: S117-28. PMID 17620747 DOI: 10.1097/01.Aids.0000279714.60935.A2  0.423
2007 Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. Aids (London, England). 21: 973-82. PMID 17457091 DOI: 10.1097/Qad.0B013E328011Ec53  0.322
2007 Groot Koerkamp B, Hunink MG, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 27: 101-11. PMID 17409361 DOI: 10.1177/0272989X06297394  0.397
2007 Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 10: 98-116. PMID 17391419 DOI: 10.1111/J.1524-4733.2006.00157.X  0.353
2007 McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage GR. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 44: 1115-22. PMID 17366461 DOI: 10.1086/512816  0.357
2007 Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 109: 1082-9. PMID 17265519 DOI: 10.1002/Cncr.22512  0.314
2007 O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US. Blood. 110: 3336-3336. DOI: 10.1182/Blood.V110.11.3336.3336  0.618
2007 Kuehne F, Chancellor J, Mollon P, Weinstein M. Pin36 Microsimulation Or Cohort Modeling? A Comparative Case Study In Hiv Infection Value in Health. 10. DOI: 10.1016/S1098-3015(10)69056-0  0.407
2007 Taylor D, Iskandar R, Delong K, Meadows E, Johnston J, Mershon J, Kerlikowske K, Weinstein M. Pcn10 Cost-Effectiveness Of Breast Cancer Risk Assessment In Primary Care Value in Health. 10. DOI: 10.1016/S1098-3015(10)68921-8  0.312
2007 Taylor D, Kruzikas D, Pandya A, Iskandar R, Gilmore K, Weinstein M. MC1 METHODS OF MODEL CALIBRATION:A COMPARATIVE APPROACH Value in Health. 10: A7. DOI: 10.1016/S1098-3015(10)68554-3  0.474
2006 Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals of Internal Medicine. 145: 797-806. PMID 17146064 DOI: 10.7326/0003-4819-145-11-200612050-00004  0.6
2006 Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999). 43: S113-8. PMID 17133193 DOI: 10.1097/01.Qai.0000248334.52072.25  0.635
2006 Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. Plos Medicine. 3: e434. PMID 17105337 DOI: 10.1371/Journal.Pmed.0030434  0.335
2006 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 24: 1043-53. PMID 17067190 DOI: 10.2165/00019053-200624110-00002  0.318
2006 Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care. 44: 990-7. PMID 17063130 DOI: 10.1097/01.Mlr.0000228021.89490.2A  0.606
2006 Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. The New England Journal of Medicine. 355: 1141-53. PMID 16971720 DOI: 10.1056/Nejmsa060247  0.726
2006 Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (London, England). 368: 679-86. PMID 16920473 DOI: 10.1016/S0140-6736(06)69252-0  0.348
2006 Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde. 96: 526-9. PMID 16841136 DOI: 10.7196/Samj.1132  0.307
2006 Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. Plos Medicine. 3: e241. PMID 16796403 DOI: 10.1371/Journal.Pmed.0030241  0.595
2006 Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. The Journal of Infectious Diseases. 194: 11-9. PMID 16741877 DOI: 10.1086/505147  0.551
2006 Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. American Journal of Preventive Medicine. 30: 498-506. PMID 16704944 DOI: 10.1016/J.Amepre.2006.01.017  0.39
2006 Groot Koerkamp B, Myriam Hunink MG, Stijnen T, Weinstein MC. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Economics. 15: 383-92. PMID 16389669 DOI: 10.1002/Hec.1064  0.315
2006 Thompson D, Taylor DC, Montoya EL, Jones SE, Weinstein MC. Potential clinical and economic impact of switching U.S. women to exemestane following 2–3 years of therapy with tamoxifen for early breast cancer Journal of Clinical Oncology. 24: 6109-6109. DOI: 10.1200/Jco.2006.24.18_Suppl.6109  0.322
2006 O’Sullivan AK, Pandya A, Thompson D, Papadopoulos G, Weinstein MC, Perfect JR, Langston A. Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S. Blood. 108: 3311-3311. DOI: 10.1182/Blood.V108.11.3311.3311  0.626
2006 Thompson D, Chhabra A, Treglia M, Healey P, O'Sullivan A, McGarry L, Weinstein M, Winkelman J. Pnl17 Economic Costs Of Chronic Primary Insomnia In The United States Value in Health. 9. DOI: 10.1016/S1098-3015(10)64566-4  0.341
2006 McGarry L, Iskandar R, Seal B, Asche C, Thompson D, Weinstein M. RS2 COST-EFFECTIVENESS OFTELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA Value in Health. 9: A6. DOI: 10.1016/S1098-3015(10)64332-X  0.324
2005 Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financing Review. 26: 67-80. PMID 17288069  0.586
2005 Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. The New England Journal of Medicine. 353: 1516-22. PMID 16207857 DOI: 10.1056/Nejmsb050564  0.405
2005 Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 41: 1316-23. PMID 16206108 DOI: 10.1086/496984  0.413
2005 Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs. Breast Cancer Research and Treatment. 93: 25-34. PMID 16184455 DOI: 10.1007/S10549-005-3380-2  0.527
2005 Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC. Can we better prioritize resources for cost-utility research? Medical Decision Making : An International Journal of the Society For Medical Decision Making. 25: 429-36. PMID 16061895 DOI: 10.1177/0272989X05276853  0.381
2005 Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. Aids (London, England). 19: 1299-308. PMID 16052085 DOI: 10.1097/01.Aids.0000180101.80888.C6  0.398
2005 Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Annals of Internal Medicine. 143: 89-99. PMID 16027450 DOI: 10.7326/0003-4819-143-2-200507190-00007  0.31
2005 Aledort JE, Hook EW, Weinstein MC, Goldie SJ. The cost effectiveness of gonorrhea screening in urban emergency departments. Sexually Transmitted Diseases. 32: 425-36. PMID 15976600 DOI: 10.1097/01.Olq.0000154501.22566.Fa  0.764
2005 Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 25: 321-9. PMID 15951459 DOI: 10.1177/0272989X05276955  0.317
2005 Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. Journal of Acquired Immune Deficiency Syndromes (1999). 39: 69-77. PMID 15851916 DOI: 10.1097/01.Qai.0000160406.08924.A2  0.747
2005 Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antiviral Therapy. 10: 41-52. PMID 15751762  0.677
2005 Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. The American Journal of Medicine. 118: 292-300. PMID 15745728 DOI: 10.1016/J.Amjmed.2004.07.055  0.726
2005 Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. The New England Journal of Medicine. 352: 586-95. PMID 15703423 DOI: 10.1056/Nejmsa042088  0.724
2005 Rinfret S, Cohen DJ, Lamas GA, Fleischmann KE, Weinstein MC, Orav J, Schron E, Lee KL, Goldman L. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. Circulation. 111: 165-72. PMID 15630030 DOI: 10.1161/01.Cir.0000151810.69732.41  0.354
2004 Romanus D, Neumann P, Earle C, Weinstein M, Tsai J, Neville B, Weeks J. Out-of-pocket costs (OPC) and time costs (TC) for patients with stage IV non-small cell lung cancer (NSCLC) and their caregivers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6021. PMID 28015101 DOI: 10.1200/Jco.2004.22.90140.6021  0.333
2004 Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology. 233: 729-39. PMID 15564408 DOI: 10.1148/Radiol.2333032052  0.355
2004 Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. Bmj (Clinical Research Ed.). 329: 733-6. PMID 15388618 DOI: 10.1136/Bmj.329.7468.733  0.326
2004 Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 7: 554-68. PMID 15367251 DOI: 10.1111/J.1524-4733.2004.75007.X  0.531
2004 Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine. 22: 4044-53. PMID 15364455 DOI: 10.1016/J.Vaccine.2004.03.059  0.365
2004 Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Economics. 13: 429-36. PMID 15127423 DOI: 10.1002/Hec.853  0.337
2004 Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 854-63. PMID 14990641 DOI: 10.1200/Jco.2004.04.158  0.591
2004 Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sanguinis. 86: 28-40. PMID 14984557 DOI: 10.1111/J.0042-9007.2004.00379.X  0.315
2004 Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ. Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. The American Journal of Cardiology. 93: 509-11. PMID 14969639 DOI: 10.1016/J.Amjcard.2003.10.060  0.342
2004 McGarry L, Thompson D, Knudsen A, Trakas K, Cookson J, Weinstein M. CS2 COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K. Value in Health. 7: 655. DOI: 10.1016/S1098-3015(10)65691-4  0.309
2004 O'Sullivan A, Thompson D, Weinstein M. Op1 Is The Current Method Of Valuing Health Outcomes In Cost-Effectiveness Analysis Valid? Value in Health. 7: 233. DOI: 10.1016/S1098-3015(10)62106-7  0.347
2003 Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal of Medicine. 115: 632-41. PMID 14656616 DOI: 10.1016/J.Amjmed.2003.07.007  0.728
2003 Zupancic JA, Richardson DK, O'Brien BJ, Schmidt B, Weinstein MC. Daily cost prediction model in neonatal intensive care. International Journal of Technology Assessment in Health Care. 19: 330-8. PMID 12862190 DOI: 10.1017/S0266462303000291  0.343
2003 Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Jama. 290: 228-37. PMID 12851278 DOI: 10.1001/Jama.290.2.228  0.302
2003 Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 9: 311-9. PMID 12814182 DOI: 10.1191/1352458503Ms903Oa  0.529
2003 Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, Lester JS, Tanabe KK, Weinstein MC. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Annals of Surgery. 237: 544-55. PMID 12677152 DOI: 10.1097/01.Sla.0000059989.55280.33  0.369
2003 Zupancic JA, Richardson DK, O'Brien BJ, Eichenwald EC, Weinstein MC. Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. Pediatrics. 111: 146-52. PMID 12509568 DOI: 10.1542/Peds.111.1.146  0.308
2003 Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 36: 86-96. PMID 12491207 DOI: 10.1086/344902  0.761
2003 Krabbe PFM, Adang EMM, Stalmeier PFM, Schackman BR, Brazier J, Weinstein MC. Letter to the editor (multiple letters) Medical Decision Making. 23: 542-543. DOI: 10.1177/0272989X03236010  0.404
2003 McGarry L, Bird A, Thompson D, Wang P, Martin S, Weinstein M. PMH26: COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA Value in Health. 6: 352. DOI: 10.1016/S1098-3015(10)64228-3  0.345
2003 McGarry L, Bird A, Thompson D, Cookson J, Martin S, Weinstein M. P.1.203 Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK European Neuropsychopharmacology. 13: S261. DOI: 10.1016/S0924-977X(03)91913-4  0.339
2002 Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. Expert Review of Vaccines. 1: 433-42. PMID 12901581 DOI: 10.1586/14760584.1.4.433  0.544
2002 Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Therapy. 7: 257-66. PMID 12553480  0.721
2002 Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 22: 506-13. PMID 12458981 DOI: 10.1177/0272989X02238299  0.525
2002 Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Archives of Internal Medicine. 162: 2478-86. PMID 12437408 DOI: 10.1001/Archinte.162.21.2478  0.608
2002 Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: The special case of end-stage renal disease treatment Medical Decision Making. 22: 417-430. PMID 12365484 DOI: 10.1177/027298902236927  0.406
2002 Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 31: 27-37. PMID 12352147 DOI: 10.1097/00126334-200209010-00004  0.721
2002 Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Archives of Internal Medicine. 162: 921-8. PMID 11966344 DOI: 10.1001/Archinte.162.8.921  0.705
2002 Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 22: 27-38. PMID 11833663 DOI: 10.1177/0272989X0202200103  0.599
2002 Amorosi S, Thompson D, Goldhaber S, Tsilimingras K, Fanikos J, Weinstein M. PCV28 A COST ANALYSIS OF “BRIDGING THERAPY” FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC ANTICOAGULATION Value in Health. 5: 172. DOI: 10.1016/S1098-3015(10)60942-4  0.367
2002 McGarry L, Thompson D, Goldhaber S, Stokes M, Weinstein M. PCV14 COST-EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY-ILL MEDICAL INPATIENTS Value in Health. 5: 166-167. DOI: 10.1016/S1098-3015(10)60928-X  0.33
2002 Grima D, Marshall D, Weinstein M, Wong J, Kleinman S, AuBuchon J. PHP26 COST-EFFECTIVENESS OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Value in Health. 5: 148. DOI: 10.1016/S1098-3015(10)60886-8  0.305
2002 Benner J, Ganz D, Weinstein M, Neumann P, Glynn R, Avorn J. HP2 IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY? Value in Health. 5: 126. DOI: 10.1016/S1098-3015(10)60834-0  0.364
2002 Benner J, Ganz D, Weinstein M, Neumann P, Glynn R, Avorn J. CV1 NONCOMPLIANCE WITH STATIN THERAPY: LOST CLINICAL BENEFITS AND IMPLICATIONS FOR COST-EFFECTIVENESS Value in Health. 5: 117. DOI: 10.1016/S1098-3015(10)60813-3  0.396
2001 Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK. Modeling for health care and other policy decisions: uses, roles, and validity. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 4: 348-61. PMID 11705125 DOI: 10.1046/J.1524-4733.2001.45061.X  0.756
2001 Goldman L, Phillips KA, Coxson P, Goldman PA, Williams L, Hunink MG, Weinstein MC. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. Journal of the American College of Cardiology. 38: 1012-7. PMID 11583874 DOI: 10.1016/S0735-1097(01)01512-1  0.352
2001 Clark C.M. J, Prosser LA, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses [3] (multiple letters) Annals of Internal Medicine. 135: 382-383. PMID 11529708  0.568
2001 Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. American Journal of Public Health. 91: 1456-63. PMID 11527782 DOI: 10.2105/Ajph.91.9.1456  0.622
2001 Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus American Journal of Medicine. 111: 140-149. PMID 11498068 DOI: 10.1016/S0002-9343(01)00780-X  0.353
2001 Weinstein MC. Should physicians be gatekeepers of medical resources? Journal of Medical Ethics. 27: 268-274. PMID 11479359 DOI: 10.1136/Jme.27.4.268  0.304
2001 Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis: An application to a policy model of Alzheimer's disease International Journal of Technology Assessment in Health Care. 17: 38-55. PMID 11329844 DOI: 10.1017/S0266462301104058  0.301
2001 Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels American Heart Journal. 141: 727-734. PMID 11320359 DOI: 10.1067/Mhj.2001.114805  0.407
2001 Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness Annals of Internal Medicine. 134: 440-450. PMID 11255519 DOI: 10.7326/0003-4819-134-6-200103200-00008  0.717
2001 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. The cost effectiveness of combination antiretroviral therapy for HIV disease. The New England Journal of Medicine. 344: 824-31. PMID 11248160 DOI: 10.1056/Nejm200103153441108  0.746
2001 Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 32: 783-93. PMID 11229847 DOI: 10.1086/319223  0.755
2001 Prosser LA, Stinnett AA, Goldman L, Weinstein MC. Cost-Effectiveness Analyses Annals of Internal Medicine. 135: 382. DOI: 10.7326/0003-4819-135-5-200109040-00022  0.614
2001 Weinstein M, Appadoo S. WW5: CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA Value in Health. 4: 190. DOI: 10.1046/J.1524-4733.2001.40203-4.X  0.312
2001 Schackman B, Goldie S, Freedberg K, Losina E, Brazier J, Weinstein M. PID6: HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? Value in Health. 4: 130. DOI: 10.1046/J.1524-4733.2001.40202-164.X  0.629
2000 Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy Aids. 14: 2543-2552. PMID 11101066 DOI: 10.1097/00002030-200011100-00017  0.423
2000 Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 20: 413-22. PMID 11059474 DOI: 10.1177/0272989X0002000405  0.752
2000 Prosser LA, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. The American Journal of Managed Care. 6: 173-9. PMID 10977418  0.531
2000 Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care Annual Review of Public Health. 21: 587-611. PMID 10884966 DOI: 10.1146/Annurev.Publhealth.21.1.587  0.366
2000 Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men American Journal of Medicine. 108: 634-641. PMID 10856411 DOI: 10.1016/S0002-9343(00)00349-1  0.373
2000 Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Annals of Internal Medicine. 132: 769-79. PMID 10819699 DOI: 10.7326/0003-4819-132-10-200005160-00002  0.556
2000 Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC. Who gets chemotherapy for metastatic lung cancer? Chest. 117: 1239-1246. PMID 10807806 DOI: 10.1378/Chest.117.5.1239  0.302
2000 Paltiel AD, Goldie SJ, Seage GR, Losina E, Weinstein MC, Cohen C, Craven DE, Freedberg KA. A Model of HIV Patient Care: Methods and Applications to the Cost-Effectiveness of Anti-Viral Therapy Sexually Transmitted Diseases. 27: 650-651. DOI: 10.1097/00007435-200011000-00026  0.424
1999 Kuntz KM, Tsevat J, Weinstein MC, Goldman L. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction Journal of the American Medical Association. 282: 2246-2251. PMID 10605977 DOI: 10.1001/Jama.282.23.2246  0.365
1999 Weinstein MC. Theoretically correct cost-effectiveness analysis Medical Decision Making. 19: 381-382. PMID 10520675 DOI: 10.1177/0272989X9901900404  0.378
1999 Weinstein MC. High-priced technology can be good value for money Annals of Internal Medicine. 130: 857-858. PMID 10366377 DOI: 10.7326/0003-4819-130-10-199905180-00021  0.348
1999 Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men Journal of the American Medical Association. 281: 1822-1829. PMID 10340370 DOI: 10.1001/Jama.281.19.1822  0.429
1999 Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 52: 1138-1138. PMID 10214734 DOI: 10.1212/Wnl.52.6.1138  0.431
1999 Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women Annals of Internal Medicine. 130: 97-107. PMID 10068381 DOI: 10.7326/0003-4819-130-2-199901190-00003  0.44
1999 Redelmeier DA, Weinstein MC. Cost-effectiveness of regulations against using a cellular telephone while driving Medical Decision Making. 19: 1-8. PMID 9917014 DOI: 10.1177/0272989X9901900101  0.396
1998 Hunink MGM, Bult JR, De Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: The joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method Medical Decision Making. 18: 337-346. PMID 9679999 DOI: 10.1177/0272989X9801800312  0.383
1998 Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures Annual Review of Public Health. 19: 125-152. PMID 9611615 DOI: 10.1146/Annurev.Publhealth.19.1.125  0.42
1998 Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 18: S93-105. PMID 9566470 DOI: 10.1177/0272989X98018002S11  0.362
1998 Gray DT, Weinstein MC. Decision and cost-utility analyses of surgical versus transcatheter closure of patent ductus arteriosus: Should you let a smile be your umbrella? Medical Decision Making. 18: 187-201. PMID 9566452 DOI: 10.1177/0272989X9801800208  0.377
1998 Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The cost-effectiveness of preventing AIDS-related opportunistic infections. Jama. 279: 130-6. PMID 9440663 DOI: 10.1001/Jama.279.2.130  0.384
1998 Bult JR, Hunink MGM, Tsevat J, Weinstein MC. Heterogeneity in the Relationship between the Time Tradeoff and Short Form-36 for HIV-Infected and Primary Care Patients Medical Care. 36: 523-532. DOI: 10.1097/00005650-199804000-00008  0.323
1997 Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 11: 159-68. PMID 10172935 DOI: 10.2165/00019053-199711020-00005  0.382
1997 Weinstein MC, Manning WG. Theoretical issues in cost-effectiveness analysis Journal of Health Economics. 16: 121-128. PMID 10167343 DOI: 10.1016/S0167-6296(96)00511-5  0.38
1997 Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, Parmley WW. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology. 30: 1741-50. PMID 9385902 DOI: 10.1016/S0735-1097(97)00391-4  0.372
1997 Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG, Torrance GW. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Economics. 6: 505-10. PMID 9353651 DOI: 10.1002/(Sici)1099-1050(199709)6:5<505::Aid-Hec294>3.0.Co;2-I  0.361
1997 Litvak E, Siegel JE, Pauker SG, Lallemant M, Fineberg HV, Weinstein MC. Whose blood is safer? The effect of the stage of the epidemic on screening for HIV. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 17: 455-63. PMID 9343804 DOI: 10.1177/0272989X9701700411  0.342
1997 Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. Journal of General Internal Medicine. 12: 551-8. PMID 9294789 DOI: 10.1046/J.1525-1497.1997.07107.X  0.424
1997 Tosteson AN, Weinstein MC, Hunink MG, Mittleman MA, Williams LW, Goldman PA, Goldman L. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation. 95: 24-30. PMID 8994412 DOI: 10.1161/01.Cir.95.1.24  0.32
1997 Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC, Diaz JH. The Role of Cost-Effectiveness Analysis in Health and Medicine Survey of Anesthesiology. 41: 330. DOI: 10.1097/00132586-199712000-00018  0.371
1996 Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. Jama. 276: 1339-41. PMID 8861994 DOI: 10.1001/Jama.276.16.1339  0.397
1996 Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Jama. 276: 1253-8. PMID 8849754 DOI: 10.1001/Jama.1996.03540150055031  0.379
1996 Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. Jama. 276: 1172-7. PMID 8827972 DOI: 10.1001/Jama.276.14.1172  0.391
1996 Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction Circulation. 94: 957-965. PMID 8790032 DOI: 10.1161/01.Cir.94.5.957  0.378
1996 Tengs TO, Meyer G, Siegel JE, Pliskin JS, Graham JD, Weinstein MC. Oregon's Medicaid ranking and cost-effectiveness: is there any relationship? Medical Decision Making : An International Journal of the Society For Medical Decision Making. 16: 99-107. PMID 8778541 DOI: 10.1177/0272989X9601600201  0.381
1996 Villari P, Fattore G, Siegel JE, Paltiel AD, Weinstein MC. Economic evaluation of HIV testing among intravenous drug users: An analytic framework and its application to Italy International Journal of Technology Assessment in Health Care. 12: 336-357. PMID 8707505  0.34
1995 Kuntz KM, Weinstein MC. Life Expectancy Biases in Clinical Decision Modeling Medical Decision Making. 15: 158-169. PMID 7783577 DOI: 10.1177/0272989X9501500209  0.314
1995 Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis : An Official Publication of the Society For Risk Analysis. 15: 369-90. PMID 7604170 DOI: 10.1111/J.1539-6924.1995.Tb00330.X  0.368
1995 Neumann PJ, Gharib SD, Weinstein MC. The cost of successful delivery with in vitro fertilization Obstetrical and Gynecological Survey. 50: 129-131. DOI: 10.1097/00006254-199502000-00023  0.358
1995 Fabrick KC, Mittleman MA, Tsevat J, Goldman PA, Williams LW, Goldman L, Weinstein MC. 901-66 Vitamin E for Coronary Heart Disease: What is at Stake? Journal of the American College of Cardiology. 25: 20A-21A. DOI: 10.1016/0735-1097(95)91543-7  0.324
1994 Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and Effectiveness of Angiotensin Converting Enzyme Inhibition in Patients With Congestive Heart Failure Archives of Internal Medicine. 154: 1143-1149. PMID 8185426 DOI: 10.1001/Archinte.1994.00420100129016  0.395
1994 Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, Weinstein MC. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation. 89: 1859-74. PMID 8149551 DOI: 10.1161/01.Cir.89.4.1859  0.322
1994 Gaspoz JM, Lee TH, Weinstein MC, Cook EF, Goldman P, Komaroff AL, Goldman L. Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. Journal of the American College of Cardiology. 24: 1249-59. PMID 7930247 DOI: 10.1016/0735-1097(94)90106-6  0.323
1993 Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis Journal of Health Economics. 12: 459-467. PMID 10131756 DOI: 10.1016/0167-6296(93)90005-Y  0.404
1993 Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction Journal of the American College of Cardiology. 22: 1697-1702. PMID 8227841 DOI: 10.1016/0735-1097(93)90598-U  0.332
1993 Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications The American Journal of Cardiology. 72. PMID 8213502 DOI: 10.1016/0002-9149(93)90015-5  0.376
1993 Gray DT, Fyler DC, Walker AM, Weinstein MC, Chalmers TC. Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus New England Journal of Medicine. 329: 1517-1523. PMID 7695658 DOI: 10.1056/Nejm199311183292101  0.324
1992 Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson ANA, Goldman L. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction New England Journal of Medicine. 327: 7-13. PMID 1598117 DOI: 10.1056/Nejm199207023270102  0.329
1992 Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, Kinosian B, Weinstein MC. Cost and health implications of cholesterol lowering. Circulation. 85: 1960-8. PMID 1572059 DOI: 10.1161/01.Cir.85.5.1960  0.339
1992 Capilouto EI, Weinstein MC, Hemenway D, Cotton D. What is the dentist's occupational risk of becoming infected with hepatitis B or the human immunodeficiency virus? American Journal of Public Health. 82: 587-589. PMID 1546781 DOI: 10.2105/Ajph.82.4.587  0.327
1991 Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among IV drug users: Modeling the impact of HIV prevalence American Journal of Public Health. 81: 1273-1279. PMID 1928525 DOI: 10.2105/Ajph.81.10.1273  0.327
1991 Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. The New England Journal of Medicine. 325: 81-6. PMID 1904989 DOI: 10.1056/Nejm199107113250202  0.333
1991 Weinstein MC. The cost-effectiveness of orphan drugs American Journal of Public Health. 81: 414-415. PMID 1900676 DOI: 10.2105/Ajph.81.4.414  0.348
1991 Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart Disease Jama: the Journal of the American Medical Association. 265: 1145-1151. PMID 1899896 DOI: 10.1001/Jama.1991.03460090093039  0.348
1991 Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane MA, Weinstein MC. A Country Of Intermediate Hbv Endemicity International Journal of Technology Assessment in Health Care. 7: 256-262. PMID 1834601 DOI: 10.1017/S026646230000564X  0.306
1991 Tosteson ANA, Weinstein MC. 12 Cost-effectiveness of hormone replacement therapy after the menopause Bailliere's Clinical Obstetrics and Gynaecology. 5: 943-959. PMID 1822828 DOI: 10.1016/S0950-3552(05)80298-6  0.365
1990 Weinstein MC. The costs of prevention Journal of General Internal Medicine. 5. PMID 2231073 DOI: 10.1007/Bf02600850  0.379
1990 Hatziandreu EE, Weinstein MC, Carlson K, Mulley AG. Cost-effectiveness study of the extracorporeal shock-wave lithotriptor International Journal of Technology Assessment in Health Care. 6: 623-632. PMID 2128082 DOI: 10.1017/S0266462300004268  0.366
1990 Tosteson ANA, Rosenthal DI, Melton LJ, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy Annals of Internal Medicine. 113: 594-603. PMID 2119161 DOI: 10.7326/0003-4819-113-8-594  0.362
1990 Weinstein MC, Coley CM, Richter JM. Medical management of gallstones: a cost-effectiveness analysis. Journal of General Internal Medicine. 5: 277-84. PMID 2115575 DOI: 10.1007/Bf02600391  0.33
1990 Weinstein MC. Principles of cost-effective resource allocation in health care organizations International Journal of Technology Assessment in Health Care. 6: 93-103. PMID 2113893 DOI: 10.1017/S0266462300008953  0.365
1989 White BA, Antczak-Bouckoms AA, Weinstein MC. Issues in the economic evaluation of community water fluoridation Journal of Dental Education. 53: 646-657. PMID 2509526 DOI: 10.1002/J.0022-0337.1989.53.11.Tb02366.X  0.396
1989 Weinstein MC. Methodologic issues in policy modeling for cardiovascular disease Journal of the American College of Cardiology. 14. PMID 2504801 DOI: 10.1016/0735-1097(89)90160-5  0.375
1988 Weinstein MC. A QALY is a QALY is a QALY - Or is it? Journal of Health Economics. 7: 289-290. PMID 10291478 DOI: 10.1016/0167-6296(88)90030-6  0.302
1988 Lee TH, Fukui T, Weinstein MC, Tosteson ANA, Goldman L. Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina Medical Decision Making. 8: 268-278. PMID 3141736 DOI: 10.1177/0272989X8800800408  0.336
1988 Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity American Journal of Public Health. 78: 1417-1421. PMID 3140681 DOI: 10.2105/Ajph.78.11.1417  0.318
1988 Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. The New England Journal of Medicine. 319: 152-7. PMID 2898733 DOI: 10.1056/Nejm198807213190306  0.367
1987 Antczak-Bouckoms AA, Weinstein MC. Cost-effectiveness Analysis of Periodontal Disease Control Journal of Dental Research. 66: 1630-1635. PMID 10872396 DOI: 10.1177/00220345870660110501  0.373
1987 Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. American Journal of Public Health. 77: 1417-26. PMID 3661794 DOI: 10.2105/Ajph.77.11.1417  0.332
1987 Weinstein MC, Read JL, MacKay DN, Kresel JJ, Ashley H, Halvorsen KT, Hutchings HC. Cost-effective choice of antimicrobial therapy for serious infections. Journal of General Internal Medicine. 1: 351-63. PMID 3098940 DOI: 10.1007/Bf02596417  0.4
1986 Weinstein MC. Challenges for Cost-effectiveness Research Medical Decision Making. 6: 194-198. PMID 3095604 DOI: 10.1177/0272989X8600600402  0.353
1986 Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term 'cost effective' in medicine New England Journal of Medicine. 314: 253-256. PMID 3079883 DOI: 10.1056/Nejm198601233140421  0.357
1985 Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease Annual Review of Public Health. 6: 41-63. PMID 2859868 DOI: 10.1146/Annurev.Pu.06.050185.000353  0.314
1985 Sandberg SI, Barnes BA, Weinstein MC, Braun P. Elective hysterectomy: benefits risks and costs. Medical Care. 23: 1067-1085. DOI: 10.1097/00005650-198509000-00005  0.318
1984 Dichter CR, Weinstein MC. Cost-effectiveness of lowering the aflatoxin tolerance level Food and Chemical Toxicology. 22: 439-445. PMID 6429018 DOI: 10.1016/0278-6915(84)90326-0  0.391
1983 Pliskin JS, Stason WB, Weinstein MC, Johnson RA, Cohn PF, McEnany MT, Braun P. Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 1: 10-28. PMID 6820456 DOI: 10.1177/0272989X8100100104  0.355
1983 Weinstein MC. Cost-effective priorities for cancer prevention Science. 221: 17-23. PMID 6407110 DOI: 10.1126/Science.6407110  0.37
1983 Doubilet P, McNeil BJ, Weinstein MC. Optimal Strategies for the Diagnosis and Treatment of Coronary Artery Disease: Analysis Using Microcomputer Medical Decision Making. 3: 23-28. PMID 6350790 DOI: 10.1177/0272989X8300300107  0.318
1983 Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause Obstetrical and Gynecological Survey. 38: 445-455. PMID 6310460 DOI: 10.1097/00006254-198308000-00001  0.401
1982 Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery Circulation. 66. PMID 6812979 DOI: 10.1007/978-3-642-69855-2_42  0.361
1981 Weinstein MC. Economic Assessments of Medical Practices and Technologies Medical Decision Making. 1: 309-330. PMID 6820459 DOI: 10.1177/0272989X8100100403  0.406
1980 Weinstein MC. Estrogen use in postmenopausal women - costs, risks, and benefits New England Journal of Medicine. 303: 308-316. PMID 6770270 DOI: 10.1056/Nejm198008073030604  0.345
1978 Weinstein MC. Prevention that pays for itself New England Journal of Medicine. 299: 307-308. PMID 96344 DOI: 10.1056/Nejm197808102990612  0.339
1977 Stason WB, Weinstein MC. Allocation of resources to manage hypertension New England Journal of Medicine. 296: 732-739. PMID 402577 DOI: 10.1056/Nejm197703312961307  0.321
1977 Weinstein MC, Stason WB. Foundations of cost effectiveness analysis for health and medical practices New England Journal of Medicine. 296: 716-721. PMID 402576 DOI: 10.1056/Nejm197703312961304  0.399
1974 Weinstein MC, Zeckhauser RJ. Use patterns for depletable and recycleable resources Review of Economic Studies. 41: 67-88. DOI: 10.2307/2296372  0.307
Show low-probability matches.